8MM atrial fibrillation market to fall to $10.5b by 2032

The decline is attributed to the drop in sales of novel oral anticoagulants.

The atrial fibrillation market across the eight major markets (8MM) is expected to decline at a negative compound annual growth rate (CAGR) of 3.2% from $14.5b in 2022 to $10.5b in 2032, said GlobalData.

The decline is attributed to the drop in sales of the four leading novel oral anticoagulants (NOACs).

NOAC sales across the 8MM are projected to fall from $13.4b in 2022 to $7.5b in the forecast period, reflecting a negative CAGR of 5.6%.

However, the losses will be offset by the introduction and uptake of novel FXI/FXIa inhibitors, said Shireen Mohammad, Senior Cardiovascular & Metabolic Disorders Analyst at GlobalData.

“In addition, the calcium channel blocker etripamil is anticipated to launch during the forecast period,” Mohammad added.

8MM: US, France, Germany, Italy, Spain, UK, Canada, and Japan.